4SA Stock Chart & Stats
€0.25
>-€0.01(-0.99%)
At close: 4:00 PM EDT
€0.25
>-€0.01(-0.99%)
Day’s Range― - ―
52-Week Range€0.12 - €0.41
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€5.31M
Enterprise Value€70.31
Total Cash (Recent Filing)€9.48M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.12
Next Earnings
Nov 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.52
Shares Outstanding21,163,902
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)3.27
Price to Sales (P/S)7.79
P/FCF Ratio-3.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.03
Revenue Forecast (FY)€948.40K
Bulls Say, Bears Say
Bulls Say
Revenue GrowthThe expanding revenue base indicates developing customer demand for AcouSort's acoustofluidic solutions. Continued adoption across cell therapy, diagnostics and research workflows could support greater scale and operating leverage.
Acoustofluidic Technology PlatformA platform that integrates into customer instruments and manufacturing workflows can create durable application breadth and switching costs. Exposure to cell therapy, diagnostics and research also provides multiple long-term routes to commercialization.
Debt-Free Balance SheetThe absence of reported debt reduces solvency risk and avoids interest burdens while the company develops its commercial base. This provides more financial flexibility than a similarly loss-making business carrying substantial leverage.
Bears Say
Deeply Negative ProfitabilityNegative gross profit and large operating losses show that the current commercial model has not reached sustainable unit economics. Persistent margin deficits could limit reinvestment capacity and require external funding until scale or pricing improves.
Persistent Cash BurnSustained negative operating and free cash flow means growth is not yet self-funded. If cash generation does not improve, AcouSort may need additional capital to maintain development and commercialization, increasing financing and dilution risk.
Shrinking Equity BaseThe sharp decline in equity reflects cumulative losses and weak returns, reducing the balance-sheet buffer available for execution. Combined with ongoing cash burn, this raises the likelihood that future expansion could depend on external financing.
4SA FAQ
What was AcouSort AB’s price range in the past 12 months?
AcouSort AB lowest stock price was €0.12 and its highest was €0.41 in the past 12 months.
What is AcouSort AB’s market cap?
AcouSort AB’s market cap is €5.31M.
When is AcouSort AB’s upcoming earnings report date?
AcouSort AB’s upcoming earnings report date is Nov 25, 2026 which is in 76 days.
How were AcouSort AB’s earnings last quarter?
AcouSort AB released its earnings results on Aug 26, 2026. The company reported -€0.015 earnings per share for the quarter.
Is AcouSort AB overvalued?
According to Wall Street analysts AcouSort AB’s price is currently Overvalued.
Does AcouSort AB pay dividends?
AcouSort AB does not currently pay dividends.
What is AcouSort AB’s EPS estimate?
AcouSort AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AcouSort AB have?
AcouSort AB has 21,163,902 shares outstanding.
What happened to AcouSort AB’s price movement after its last earnings report?
AcouSort AB reported an EPS of -€0.015 in its last earnings report. Following the earnings report the stock price went down -7.631%.
Which hedge fund is a major shareholder of AcouSort AB?
Currently, no hedge funds are holding shares in DE:4SA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
AcouSort AB
AcouSort AB (publ), a technology company, develops components and instruments used in the diagnostics, analytics, and cell therapy processing markets. It offers AcouTrap, a benchtop research instrument for sample preparation of cells, extracellular vesicles, bacteria, and viruses from various media; AcouPlasma, an module that enables in-line analysis of blood plasma from whole blood samples; AQC Module, an in-line optical analysis of particle suspensions for quality control or monitoring applications; and AcouWash, a benchtop research instrument for label-free separation of target cells from various samples. The company has collaboration agreement with global life science company to develop cell therapy and other elements of the future automated systems. AcouSort AB (publ) was founded in 2010 and is based in Lund, Sweden.